Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Continuation Intravenous Ketamine in Major Depressive Disorder - Modification: Lithium for Relapse Prevention


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT00548964

Organisation Name: Icahn School of Medicine at Mount Sinai

Overal Status: Completed

Start Date: October 2007

Last Update: May 23, 2014

Lead Sponsor: James Murrough

Brief Summary: As of May 21st, 2012, the purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant depression (TRD) who respond to an initial series of ketamine infusions. Ketamine is a Food and Drug Administration approved anesthetic (a drug used to produce loss of consciousness before and during surgery). Ketamine is not approved for the treatment of major depressive disorder and is considered experimental in this study.

Conditions:
  • Major Depressive Disorder


Total execution time in seconds: 0.45376205444336